Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $875,550.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 65,000 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Gad also recently made the following trade(s):

• On Monday, September 16th, Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $12.97, for a total value of $389,100.00.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $14.00 on Friday. Y-mAbs Therapeutics, Inc. has a one year low of $4.69 and a one year high of $20.90. The company’s fifty day moving average price is $12.84 and its two-hundred day moving average price is $13.49. The company has a market capitalization of $614.36 million, a price-to-earnings ratio of -28.57 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $22.80 million during the quarter, compared to the consensus estimate of $23.09 million. During the same period in the previous year, the business posted ($0.14) earnings per share. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

YMAB has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. BMO Capital Markets decreased their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Truist Financial initiated coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new stake in Y-mAbs Therapeutics during the fourth quarter valued at about $562,000. Ameritas Investment Partners Inc. grew its holdings in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Y-mAbs Therapeutics by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after buying an additional 1,657 shares during the period. Boston Partners acquired a new position in shares of Y-mAbs Therapeutics during the first quarter worth approximately $556,000. Finally, Rice Hall James & Associates LLC boosted its position in shares of Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after acquiring an additional 3,589 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.